Osimertinib vs STX-241
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Osimertinib · Tagrisso
Marketed by AstraZeneca
NCT02151981 · Phase 3 · completed
The trial was randomized and actively controlled, with 279 patients receiving osimertinib and 140 receiving platinum-based chemotherapy, but treatment assignment was not blinded. Its primary clinical endpoint, investigator-assessed progression-free survival, favored osimertinib significantly (hazard ratio 0.30; p<0.001), supporting moderate-strength evidence rather than the strongest level because the study was open-label.
Next expected readout: November 2026 · NCT05998993 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) (met)
Result source: NCT02151981
STX-241
Developed by Pierre Fabre Medicament
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2027 · NCT06567015 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Osimertinib | STX-241 |
|---|---|---|
| PFS, median | 19.5 vs 22.0vs GefitinibNCT028568931 other result
| —Not reported |
| OS, median | —Not posted · NCT05015608 | —Not reported |
| ORR | 76%bNCT02789345 | —Not reported |
| Duration of response, median | 13.4bNCT02789345 | —Not reported |
PFS, median
- Osimertinib
- 19.5 vs 22.0vs GefitinibNCT02856893
1 other result
- 11.0 NCT02789345
- STX-241
- —Not reported
OS, median
- Osimertinib
- —Not posted · NCT05015608
- STX-241
- —Not reported
ORR
- Osimertinib
- 76%bNCT02789345
- STX-241
- —Not reported
Duration of response, median
- Osimertinib
- 13.4bNCT02789345
- STX-241
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
STX-241: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Osimertinib: 4 of 4 rows · STX-241: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Osimertinib |
|---|---|
| Dropout rate | 62.3%a NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results100%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 77.3%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 3.8%a NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results0%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 4.5%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 17%a NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results33.3%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 36.4%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a diarrhea 50.9% dry skin 41.5% weight loss 35.8% NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more resultscough 100% diarrhoea 100% arthralgia 66.7% NCT02789345 · Phase 1 · registry result, not featured evidence · combination diarrhoea 63.6% hypertension 63.6% decreased appetite 40.9% NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Osimertinib
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Osimertinib's landscape · STX-241's landscape